Methotrexate treatment in pediatric crohn disease patients intolerant or resistant to purine analogues

Journal of Pediatric Gastroenterology and Nutrition

Volumn 48, Issue 5, 2009, Pages 526-530

  Weiss, B ^a   Lerner, A ^b   Shapiro, R ^c   Broide, E ^d   Levine, A ^a   Fradkin, A ^a   Bujanover, Y ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c SCHNEIDER CHILDREN'S HOSPITAL   (United States)

^d Asaf Harofe Medical Center   (Israel)

Author keywords

Azathioprine; Children; Crohn disease; Immunomodulators; Methotrexate

Indexed keywords

LIVER ENZYME; MERCAPTOPURINE; METHOTREXATE; STEROID;

ADOLESCENT; ARTICLE; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; CROHN DISEASE; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MALE; NAUSEA AND VOMITING; PANCREATITIS; PRIORITY JOURNAL; REMISSION; SIDE EFFECT;

6-MERCAPTOPURINE; ADMINISTRATION, ORAL; ADOLESCENT; AZATHIOPRINE; CHILD; CROHN DISEASE; DRUG RESISTANCE; DRUG TOLERANCE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, SUBCUTANEOUS; MALE; METHOTREXATE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; STEROIDS;

EID: 67650882729     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPG.0b013e318196df3e     Document Type: Article

References (20)

1. Teml A, Schaeffeler E, Herrlinger KR, et al. Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing. Clin Pharmacokinet 2007;46:187-208.
2. Hyames J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2007;132:863-73.
3. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med 1995;332:292-7.
4. Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. N Engl J Med 2000;342:1627-32.
5. Lemann M, Zenjari T, Bouhnik Y, et al. Methotrexate in Crohn's disease: long-term efficacy and toxicity. Am J Gastroenterol 2000;95:1730-4.
6. Mack DR, Young R, Kaufman SS, et al. Methotrexate in patients with Crohn's disease after 6-mercaptopurine. J Pediatr 1998; 132:830-5.
7. Uhlen S, Bellbouab R, Narebski K, et al. Efficacy of methotraxate in pediatric Crohn's disease: a French multicenter study. Inflamm Bowel Dis 2006;12:1053-7.
8. Turner D, Grossman AB, Rosh J, et al. Methotrexate following unsuccessful thiopurine therapy in pediatric Crohn's disease. Am J Gastroenterol 2007;12:2804-12.
9. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet 1980;1:514.
10. Dixon WJ, Chief ed. BMDP statistical software. Los-Angeles: University of California Press; 1993.
11. Kirshner BS. Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology 1998;115:813-21.
12. Soon SY, Asari A, Yanez M, et al. Experience with the use of low-dose methotrexate for inflammatory bowel disease. Eur J Gastroenterol Hepatol 2004;16:921-6.
13. Ravikumara M, Hinsberger A, Spray CH. Role of methotrexate in the management of Crohn's disease. J Pediatr Gastroenterol Nutr 2007;44:427-30.
14. Hoekstra M, Haagsma C, Neef C, et al. Bioavailability of higher dose methotrexate comparing oral and subcutaneous ad ministration in patients with rheumatoid arthritis. J Rheumatol 2004; 31:645-8.
15. Jundt JW, Browne BA, Fiocci GP, et al. A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing. J Rheumatol 1993; 20:1845-9.
16. Teresi ME, Crom WR, Choi KE, et al. Methotrexate bioavailability after oral and intramuscular administration in children. J Ped 1987;110:788-92.
17. Balis FM, Savitch JL, Bleyer WA. Pharmacokinetics of oral methotrexate in children. Cancer Res 1983;43:2342-5.
18. Sun JH, Das KM. Low-dose oral methotrexate for maintaining Crohn's disease remission: where we stand. J Clin Gastro 2005; 39:751-6.
19. Stephens MC, Baldassano RN, York A, et al. The bioavailability of oral methotrexate in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2005;40:445-9.
20. Ardizzone S, Bollani S, Manzionna G, et al. Compaison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomized, investigator-blind study. Dig Liver Dis 2003;35:619-27.